Flare Therapeutics

Flare Therapeutics is a clinical-stage biotechnology company headquartered at 400 Technology Square, Cambridge, Massachusetts, developing small-molecule precision medicines against transcription factors — a target class long considered undruggable. Its platform combines a "switch site" hypothesis with cell-based ligand discovery and chemoproteomics to find binding pockets on transcription factors that control cancer cell states. The company launched publicly in May 2021 with an $82 million Series A led by Third Rock Ventures, and closed an $85 million insider-led Series C on 30 June 2026 led by Third Rock Ventures and Nextech Invest with Pfizer Ventures, Boxer Capital, GordonMD Global Investments, Invus, Casdin Capital, Eli Lilly, Novartis, Agent Capital and Eventide Asset Management participating, appointing Anna Protopapas as Chief Executive Officer at the same time. Its clinical-stage lead FX-909 is a PPARG inverse agonist in advanced urothelial cancer; FX-111 is an androgen-receptor-directed program in prostate cancer that received FDA IND clearance ahead of a clinical start in the third quarter of 2026. Flare also runs a discovery collaboration with Roche on undrugged transcription factor targets in oncology. Flare Therapeutics operates no developer program and publishes no product API, developer portal or API documentation. The only machine-readable surface reachable without credentials is the WordPress REST content API behind www.flaretx.com, catalogued here.

Flare Therapeutics publishes 1 API on the APIs.io network: Content API. Tagged areas include Company, biotechnology, pharmaceuticals, oncology, and precision-medicine.

Flare Therapeutics’ developer surface includes product news, authentication, and 21 more developer resources.

🌐 Visit website 📡 Source on GitHub
30.9/100 thin ▬ flat Agent 37/100 agent ready Full breakdown ↓
scored 2026-08-17 · rubric v0.11.0
1 APIs
Companybiotechnologypharmaceuticalsoncologyprecision-medicinetranscription-factorsdrug-discoveryclinical-trialslife-sciencescontent-api

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-08-17 · rubric v0.11.0
Composite quality — 30.9/100 · thin
Contract Quality 10.5 / 21
Developer Ergonomics 3.0 / 17
Commercial Clarity 3.6 / 17
Operational Transparency 0.6 / 11
Governance 2.1 / 10
Discoverability 6.5 / 9
Regulatory Posture 4.7 / 15
Agent readiness — 37/100 · agent ready
Machine-Readable Contract 18 / 18
Agentic Access Contract 0 / 10
MCP Server 0 / 12
Machine-Readable Auth 10 / 10
Idempotency 0 / 9
Stable Error Semantics 8 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 7 / 7
Typed Event Surface 0 / 6
Agent Skills 5 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/flare-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

APIs 1

Individual APIs this provider publishes, each with its own machine-readable definition.

Flare Therapeutics Content API

The anonymously readable WordPress REST content API behind www.flaretx.com — the 42-item corporate news archive, 14 corporate pages, a 419-item media library, the category taxon...

Open Collections 1

Open, tool-agnostic API collections (OpenAPI-derived and Bruno).

Flare Therapeutics Content API

OPEN COLLECTION

Pricing Plans 1

Published pricing tiers and plan structures.

Flare Therapeutics Plans Pricing

0 plans

PLANS

Rate Limits 1

Documented rate limits and quota policies.

Flare Therapeutics Rate Limits

0 limits

RATE LIMITS

Security Posture 2

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Flare Therapeutics Authentication

0 schemes

SECURITY

Flare Therapeutics Domain Security

TLSv1.3 · HSTS · DMARC

SECURITY

Resources

Agent Surfaces 2

MCP servers, agent skills, and machine-readable catalogs

LLMsTxt
LLMsTxt
 AgentSkill
AgentSkill

Design & Contract 5

Pagination, idempotency, versioning, errors, and events

Conventions
Conventions
 Conformance
Conformance
 ErrorCatalog
ErrorCatalog
 Lifecycle
Lifecycle
 DataModel
DataModel

Build 1

SDKs, sample code, and the tooling you integrate with

GitHubOrganization
GitHubOrganization

Access & Security 2

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity
 Authentication
Authentication

Operate 1

Status, limits, changes, and where to get help

Contact
Contact

Commercial 2

Pricing, plans, and the legal terms of use

PrivacyPolicy
PrivacyPolicy
 TermsOfService
TermsOfService

Company 6

The organization behind the API

Website
Website
 About
About
 News
News
 BlogRSS
BlogRSS
 Careers
Careers
 LinkedIn
LinkedIn

Other 4

Properties that don't map to a standard resource type

Science
Science
 Pipeline
Pipeline
 Publications
Publications
 SecondaryMarket
SecondaryMarket

Source (apis.yml)

apis.yml Raw ↑ 
aid: flare-therapeutics
name: Flare Therapeutics
description: Flare Therapeutics is a clinical-stage biotechnology company headquartered at 400 Technology Square, Cambridge,
  Massachusetts, developing small-molecule precision medicines against transcription factors — a target class long considered
  undruggable. Its platform combines a "switch site" hypothesis with cell-based ligand discovery and chemoproteomics to find
  binding pockets on transcription factors that control cancer cell states. The company launched publicly in May 2021 with
  an $82 million Series A led by Third Rock Ventures, and closed an $85 million insider-led Series C on 30 June 2026 led by
  Third Rock Ventures and Nextech Invest with Pfizer Ventures, Boxer Capital, GordonMD Global Investments, Invus, Casdin Capital,
  Eli Lilly, Novartis, Agent Capital and Eventide Asset Management participating, appointing Anna Protopapas as Chief Executive
  Officer at the same time. Its clinical-stage lead FX-909 is a PPARG inverse agonist in advanced urothelial cancer; FX-111
  is an androgen-receptor-directed program in prostate cancer that received FDA IND clearance ahead of a clinical start in
  the third quarter of 2026. Flare also runs a discovery collaboration with Roche on undrugged transcription factor targets
  in oncology. Flare Therapeutics operates no developer program and publishes no product API, developer portal or API documentation.
  The only machine-readable surface reachable without credentials is the WordPress REST content API behind www.flaretx.com,
  catalogued here.
image: https://www.flaretx.com/wp-content/uploads/2021/05/Flare-website-social-card-051221.jpg
url: https://raw.githubusercontent.com/api-evangelist/flare-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: profiled
x-tier-reason: enriched
specificationVersion: '0.20'
created: '2026-08-12'
modified: '2026-08-12'
tags:
- Company
- biotechnology
- pharmaceuticals
- oncology
- precision-medicine
- transcription-factors
- drug-discovery
- clinical-trials
- life-sciences
- content-api
apis:
- aid: flare-therapeutics:flare-therapeutics-content-api
  name: Flare Therapeutics Content API
  description: The anonymously readable WordPress REST content API behind www.flaretx.com — the 42-item corporate news archive,
    14 corporate pages, a 419-item media library, the category taxonomy, cross-content search, type/taxonomy/status discovery
    documents and an oEmbed 1.0 provider endpoint. Flare Therapeutics publishes no OpenAPI for it; the specification in this
    repo is an API Evangelist derivation of the live route index, restricted to operations verified to return data anonymously
    on 2026-08-12.
  humanURL: https://developer.wordpress.org/rest-api/
  baseURL: https://www.flaretx.com/wp-json
  tags:
  - content
  - news
  - media
  - search
  properties:
  - type: OpenAPI
    url: openapi/flare-therapeutics-content-openapi.yml
  - type: Overlay
    url: overlays/flare-therapeutics-content-overlay.yaml
  - type: Authentication
    url: authentication/flare-therapeutics-authentication.yml
  - type: ErrorCatalog
    url: errors/flare-therapeutics-problem-types.yml
  - type: Conventions
    url: conventions/flare-therapeutics-conventions.yml
  - type: DataModel
    url: data-model/flare-therapeutics-data-model.yml
  - type: Lifecycle
    url: lifecycle/flare-therapeutics-lifecycle.yml
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/flare-therapeutics-domain-security.yml
- type: Website
  url: https://www.flaretx.com/
- type: About
  url: https://www.flaretx.com/about/
- type: Science
  url: https://www.flaretx.com/science/
- type: Pipeline
  url: https://www.flaretx.com/pipeline/
- type: Publications
  url: https://www.flaretx.com/publications/
- type: News
  url: https://www.flaretx.com/news/
- type: BlogRSS
  url: https://www.flaretx.com/feed/
- type: Careers
  url: https://www.flaretx.com/join-us/
- type: Contact
  url: https://www.flaretx.com/contact/
- type: PrivacyPolicy
  url: https://www.flaretx.com/privacy-policy/
- type: TermsOfService
  url: https://www.flaretx.com/terms-of-use/
- type: LinkedIn
  url: https://www.linkedin.com/company/flare-therapeutics
- type: GitHubOrganization
  url: https://github.com/FlareTx
- type: SecondaryMarket
  url: https://forgeglobal.com/flare-therapeutics_stock/
- type: Authentication
  url: authentication/flare-therapeutics-authentication.yml
- type: Conventions
  url: conventions/flare-therapeutics-conventions.yml
- type: Conformance
  url: conformance/flare-therapeutics-conformance.yml
- type: ErrorCatalog
  url: errors/flare-therapeutics-problem-types.yml
- type: Lifecycle
  url: lifecycle/flare-therapeutics-lifecycle.yml
- type: DataModel
  url: data-model/flare-therapeutics-data-model.yml
- type: LLMsTxt
  url: llms/flare-therapeutics-llms.txt
- type: AgentSkill
  url: skills/_index.yml
x-enrichment:
  date: '2026-08-12'
  status: enriched
  artifacts_added: 17
  pass: local-v1